(Total Views: 138)
Posted On: 05/28/2024 4:57:54 PM
Post# of 156
NetworkNewsBreaks – Clene Inc. (NASDAQ: CLNN) Issues Update on NIH-Funded Program for CNM-Au8® in ALS
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, has announced several key updates on its National Institutes of Health (“NIH”) funded Accelerating Access to Critical Therapies Expanded Access Program for CNM-Au8® compassionate use (“EAP”) in ALS. Late last year, in collaboration with Columbia University and Synapticure, Clene announced the award of a four-year grant from the National Institute of Neurological Disorders and Stroke (“NINDS”), part of the NIH, to support an EAP for Clene’s investigational drug CNM-Au8 in ALS. “CNM-Au8 treatment has been associated with lowered risk of death and delayed clinical worsening, all while being very well-tolerated, in both of our independent Phase 2 clinical studies,” said Rob Etherington, CEO of Clene. “Data from EAP programs, which usually include a broader ALS population than clinical trials, can supplement the safety and other meaningful data gathered from clinical studies. We are grateful for the NIH’s recognition to fund this important initiative and are pleased to provide this EAP for the ALS community. We are also grateful to the FDA for approving this EAP, working alongside Columbia University and Synapticure, to enable people who are living with this devastating disease access to our investigational drug CNM-Au8.”
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
Clene (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, has announced several key updates on its National Institutes of Health (“NIH”) funded Accelerating Access to Critical Therapies Expanded Access Program for CNM-Au8® compassionate use (“EAP”) in ALS. Late last year, in collaboration with Columbia University and Synapticure, Clene announced the award of a four-year grant from the National Institute of Neurological Disorders and Stroke (“NINDS”), part of the NIH, to support an EAP for Clene’s investigational drug CNM-Au8 in ALS. “CNM-Au8 treatment has been associated with lowered risk of death and delayed clinical worsening, all while being very well-tolerated, in both of our independent Phase 2 clinical studies,” said Rob Etherington, CEO of Clene. “Data from EAP programs, which usually include a broader ALS population than clinical trials, can supplement the safety and other meaningful data gathered from clinical studies. We are grateful for the NIH’s recognition to fund this important initiative and are pleased to provide this EAP for the ALS community. We are also grateful to the FDA for approving this EAP, working alongside Columbia University and Synapticure, to enable people who are living with this devastating disease access to our investigational drug CNM-Au8.”
NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://nnw.fm/CLNN
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or republished: http://NNW.fm/Disclaimer
(0)
(0)
